β-secretase had no other essential functions. Willem et al. now show that β-secretase does have another substrate-type III neuregulin 1 (NRG1). NRG1 is essential to peripheral nerve myelination, in which myelin is supplied by Schwann cells to insulate axons and facilitate rapid electric transmission. A key to this discovery was the developmental expression pattern of β-secretase in mice and the finding that its activity increases during the early postnatal period, a time of extensive myelination and bundling of axons. The authors also show that type III NRG1 and β-secretase are expressed together in neurons. Myelin sheaths surrounding axons are strikingly thinner in mice lacking β-secretase (BACE1 -/-) relative to wild-type mice, and bundling of small-diameter axons is also impaired. This phenotype is also seen in mice haploinsufficient for NRG1 (8, 9) , which suggests that β-secretase-mediated cleavage of NGR1 may play a critical role in myelination (see the figure) . Indeed, large amounts of uncleaved NRG1 accumulate in BACE1 -/-mice.
Future work must address the question of whether the biologically active extracellular domain of type III NRG1 is merely presented by the axonal membrane to an adjacent Schwann cell after a single juxtamembrane cut by β-secretase or whether it is released from axons by some regulated dual cleavage. Work by Michailov et al. (8) and Taveggia et al. (9) have shown the importance of type III NRG1 in myelination, but, like Willem et al., they did not exclude dual cleavage of NRG1 that would release a fragment extracellularly. It remains to be shown whether β-secretase acts alone or in concert with other enzymes such an ADAM (a disintegrin and metalloprotease) or TACE (TNF-α converting enzyme), which are both involved in NRG1 shedding (10) . Type III NRG1 is also a substrate for regulated intramembrane proteolysis by γ-secretase, which releases a soluble intracellular domain that is translocated into the nucleus and activates transcription (11) .
Is there any truly safe strategy of targeting amyloid pathogenesis in Alzheimer's disease? Aβ is produced and secreted throughout life. The major pathological difference in Alzheimer's disease seems to be a change in conformation of the peptide from a random-coil monomer to a shape associated with the formation of oligomeric aggregates. Targeting these pathologically misfolded conformations may prove to be a safer strategy because they appear to be specific to the disease state.
Although this discovery of the role of β-secretase in myelination is reason for caution, pharmacological inhibition of both β-secretase and γ-secretase may still prove to be therapeutically beneficial. Partial inhibition of their proteolytic activities may be sufficient to lower the amount of Aβ to a level that may delay the onset and progression of the disease without producing intolerable side effects. Delaying the age of onset by even 5 years would have an enormous impact in lowering the incidence of disease in the population. And that seems like a risk worth taking. L ong before the advent of written records, our ancestors used yeast to turn sugar into carbon dioxide and ethanol. Today, we are no longer limited to fermentation products naturally excreted by bacteria and fungi. Using the tools of genetic engineering, we can direct microorganisms to make proteins, DNA, carbohydrates, and small molecules (1). These "biomolecule factories" also serve as experimental systems for studying biosynthesis; in turn, such studies often facilitate efforts to manipulate biosynthetic pathways to make new products.
Projects aiming to direct the biosynthesis of small molecules may seek to make new compounds, make natural compounds in unnatural organisms, or alter the metabolic flux through a particular biosynthetic pathway.
Here we use three examples to illustrate the state of the art in directed biosynthesis and highlight its future prospects. Our first example involves the antitumor agent echinomycin from the soil bacterium Streptomyces lasaliensis. Like proteins, echinomycin is a polypeptide, but the similarities end there. Whereas proteins are synthesized by the ribosome, echinomycin is produced by an enormous assembly-line enzyme called a nonribosomal peptide synthetase (NRPS) (2) . This synthetase is similar in size to a ribosome-yet it makes only a single peptide product. Many bacteria and fungi invest heavily in such synthetases, devoting more than 5% of their genome to the production of toxins, iron scavengers, and surfactants (3).
One difference between ribosome-synthesized proteins and nonribosomal peptides is that the latter are often cyclic rather than linear. Cyclization makes the structure of these peptides more rigid; this is usually required for their biological activity. The protein domains from NRPSs that catalyze cyclization have been used as purified enzymes to cyclize small libraries of synthetic peptides, creating unnatural derivatives of natural nonribosomal peptides (4, 5) .
In addition to being cyclic, echinomycin has a second conformational constraint: Two of its cysteine residues are linked by a chemical bond known as a thioether. Because thioether bonds cannot be cleaved by biological reductants, they are more stable than the cysteine-linking disulfide bonds commonly found in proteins.
To study the biosynthesis of echinomycin, Watanabe et al. inserted the 16 genes responsible for its production into the bacterium Escherichia coli (6) . The resulting strain proGenetic engineering is revealing biosynthetic pathways for synthesis of small molecules and avenues toward cheaper syntheses, potentially providing access to better drugs. duced echinomycin and set the stage for studying the formation of its thioether crosslink. In echinomycin, the thioether is embedded in a stable chemical group known as a thioacetal. The authors show that this thioacetal is formed in an unusual methylationrearrangement sequence from two cysteine side chains initially linked by a less stable disulfide bond. This reaction sequence is catalyzed by a single enzyme (see the figure, top panel). Knowledge of this enzymatic process may enable similar cross-links to be formed in synthetic peptide drug candidates, stabilizing them against proteolysis.
The production of echinomycin in E. coli is also important for its future prospects as an antitumor drug. Given that E. coli are easy to manipulate genetically, the echinomycin NRPS could be engineered to create echinomycin analogs that would be difficult to synthesize chemically. For example, Miao et al. have taken advantage of the modular organization of NRPSs, replacing monomer-incorporating modules with foreign counterparts to create unnatural derivatives of their smallmolecule products (7).
Our second example involves monensin, an antiparasitic and antibacterial agent that is used widely in cattle and chicken feed as a growth promoter. Produced by the soil bacterium Streptomyces cinnamonensis, monensin belongs to a family of molecules called polyethers that includes some of the deadliest poisons known (8) . Monensin is made by a polyketide synthase; such synthases are similar to NRPSs but use building blocks derived from acetate instead of amino acids (2). However, the final structure of monensin-with its five oxygencontaining rings-looks very different from the linear precursor made by its synthase.
To investigate this molecular metamorphosis, Gallimore et al. coupled genetic evidence from S. cinnamonensis with biophysical analysis of a protein responsible for part of this transformation. They deduce that this complex rearrangement is probably a twostep process (see the figure, middle panel) (9) . First, one enzyme converts the three carboncarbon double bonds to oxygen-containing three-membered rings (epoxides). In the second step of monensin rearrangement, an enzyme initiates an epoxide-opening chain reaction that forms the five rings of monensin, dramatically reconfiguring the topology of its carbon backbone.
Unlike the module exchange and enzymatic cyclization strategies of directing nonribosomal peptide biosynthesis, knowledge of how enzymes control the epoxide-opening cascades that form polyethers remains very limited. Future investigations will show how these enzymes can be engineered to create derivatives of natural polyethers with new topologies and biological activities.
Our final example involves artemisinin, a highly effective antimalarial drug that is naturally produced by the sweet wormwood tree. Artemisinin is readily available in industrialized countries, but its supply is limited in the developing world by its high cost, due in part to the long generation time of the sweet wormwood tree and the challenge of isolating artemisinin from other small molecules produced by the tree.
To provide a cheaper, more renewable source of artemisinin, Keasling and co-workers have inserted the genes responsible for the biosynthesis of its late-stage precursors in E. coli and the bakers' yeast Saccharomyces cerevisiae (see the figure, bottom panel) (10, 11) . Artemisinin belongs to a class of small molecules known as terpenes, which include cholesterol, testosterone, and estrogen. All terpenes are made from the same set of linear precursor molecules, which are molded like clay into a variety of shapes by enzymes called terpene cyclases (12) . These enzymes play the role of the potter and the kiln, first folding the linear precursor into a specific conformation and then setting off a cascade of bond-forming events that locks the shape in place.
In the case of artemisinin, a terpene cyclase folds its linear precursor into amorphadiene, a molecule with two fused six-membered rings. Because E. coli make very little of the terpene building block isopentenyl pyrophosphate (IPP), Keasling et al. enhanced production by inserting the IPP biosynthetic genes from S. cerevisiae. When they added a synthetic terpene cyclase gene, the resulting E. coli produced 24 mg/liter of this early-stage artemisinin precursor (10) . In a promising follow-up study, the same group reconstituted the pathway one step further in S. cerevisiae, producing 100 mg/liter of the late-stage artemisinin precursor artemisinic acid (11) , which can be converted to artemisinin in a simple synthetic process. This work breaks new ground in expanding the biosynthetic capabilities of E. coli and S. cerevisiae and is a terrific example of how directed biosynthesis can be applied to solve pressing problems in the supply of small molecules. Future advances in the directed biosynthesis of small molecules will be driven by a mixture of technology and creativity. Improvements in gene synthesis technology will facilitate the construction of increasingly large sets of genes that comprise natural and artificial biosynthetic pathways, and less costly DNA sequencing technologies will drive the expansion of sequencing projects to identify biosynthetic genes for uncharacterized small molecules. The production of small molecules in heterologous microbial hosts (13) will provide cost-effective sources of drugs, while engineering of biosynthetic enzymes (14, 15) will provide access to a rich variety of "unnatural natural products" with improved properties or new biological activities. These advances will improve our ability to control the shape and topology of small molecules, allowing us to create new small-molecule conformers that interact specifically with biological targets.
A lmost 200 planets have been discovered around distant stars, revealing a rich and unanticipated variety among planetary systems (1) . As unlikely as it seemed only a decade ago, we are now beginning to appreciate our own solar system as just one among many possible outcomes of planetary evolution. How much of this variety is due to normal random events in the young planetary systems and how much depends on fundamental properties of the star and the initial characteristics of the matter that formed the planets are questions at the forefront of planetary research. One can extrapolate backwards from the observed planetary configurations and dynamics to try to answer these questions, but a parallel approach is to probe planet-forming disks themselves for clues to how a planet is made. Astronomers are working furiously to discover and characterize these disks. On page 621 of this issue, Lagage et al. (2) describe their observations of a very young disk. Because it surrounds a relatively rare type of star several times as massive as the Sun, their observations provide a different perspective on the nature of possible planet-forming disks, thereby contributing to a greater understanding of the process.
The broad outlines of star and planet formation are now clear. Interstellar clouds clump and collapse, the core of each compressed knot heating up enough to fuse hydrogen and become a star, the remaining knot material settling into a disk that coalesces into planets within a few million years (3) . Using an infrared camera on an 8-m telescope operated in Chile by the European Southern Observatory, Lagage et al. have imaged a disk that surrounds the star HD 97048. The infrared radiation is emitted by the disk's small solid dust particles that have been warmed by the star's ultraviolet light. The disk they see extends out to at least 370 astronomical units (AU) from the star (1 AU is the average distance of the Earth from the Sun), which is 10 times as large as the orbit of Pluto.
Images of such disks around other stars have been obtained (4) , but a combination of features makes this observation unique. HD 97048 is only about 3 million years old and thus close to the critical stage of planet formation. The star is several times as massive as our Sun, which lets us see how the possible planetforming disk environment compares to those observed around the much more common lower-mass stars. What makes the observation especially intriguing, however, is a distinct distortion in the image of HD 97048. There is an asymmetric brightness distribution that indicates Lagage et al. are seeing the surface of a tilted flared disk (see the figure) . A flared disk is like a saucer that is thicker at the edge than at the center, with the surfaces on opposite sides of the saucer being bowls that face away from each other. Dust particles residing on these bowl-shaped surfaces are easily illuminated by the star located at the center of the bowl. (Lagage et al. actually detect very large ultraviolet-excited molecules called polycyclic aromatic hydrocarbons, or PAHs, which in many ways behave like very tiny dust grains.) If the disk is opaque, then we can see only the bowl-shaped surface tilted toward us. For an arbitrary angular tilt of the disk to our line of sight, circles inscribed on the surface of the bowl and concentric with the star appear as ellipses with their centers systematically shifted farther away from the star the larger the ellipse is, exactly as Lagage et al. have observed. The ellipses represent contours of constant infrared inten-
The distorted shape of a dusk disk around a young star suggests that plenty of raw material still exists, even after 3 million years, to form giant gas planets.
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